ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$11.87
-0.02 (-0.17%)
âŧ
5d:
+4.86%
30d:
-5.19%
90d:
+13.16%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ZVRA is fairly priced but lacks strong directional signals. At 3.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ZVRA is fairly priced but lacks strong directional signals. At 3.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.76
Based on -2.0% avg growth
INTRINSIC VALUE TODAY
$6.06
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $11.87, which is considered fair relative to its 30-day fair value range of $10.19 to $12.62. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.6) compared to its historical average (10.3). At these levels, the market is pricing in 3.9% annual earnings growth.
Technical Outlook: Technically, ZVRA is in a uptrend. The price is approaching resistance at $12.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZVRA scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+106.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZVRA is in a uptrend. The price is approaching resistance at $12.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZVRA scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+106.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.19 -
$12.62
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.3%
Protect Your Profits
Holding ZVRA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 106.1% below Wall St target ($25.00)
- BULLISH: Expecting earnings turnaround to 3.9% growth with 53.3% revenue growth
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.19 -
$12.62
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.81
Resistance Level
$12.18
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.55
Wall Street Target
$25.00
(+106.1%)
Revenue Growth (YoY)
53.3%
Earnings Growth (YoY)
-88.4%
Profit Margin
42.8%
Valuation Premium vs History
+3.9% premium
PE vs Historical
11.6 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.9%
(market-implied from PE analysis)
1-Year Target
$12.60
(+4%)
2-Year Target
$13.09
(+8%)
3-Year Target
$13.61
(+12%)
3-Yr Target (if PE normalizes)
(PE: 12â10)
PE COMPRESSION
$12.13
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: -7.9%)
$16.47
(+36%)
Base:
(SPY PE: 11.6, Growth: -7.9%)
$9.48
(-22%)
Bear:
(PE: 9.8, Growth: -7.9%)
$8.06
(-34%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 12.44 | Current EPS (TTM): $0.93
Bull Case
$14.37
(+21%)
Analyst growth 12.9%, PE expands to 13.7
Base Case
$13.06
(+10%)
Market implied 12.9%, PE stable at 12.4
Bear Case
$7.87
(-34%)
Severe decline -20.0%, PE contracts to 10.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 11:20 PM ET
Data refreshes hourly during market hours. Next update: 12:20 AM
Data refreshes hourly during market hours. Next update: 12:20 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
